Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

Blueprint Medicines Corp (BPMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Blueprint Medicines Corp (BPMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Blueprint Medicines Corp (BPMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Blueprint Medicines Corp (BPMC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, is a drug discovery company that develops drugs for the treatment of cancers and rare diseases. The company discovers and develops selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-554, used in advanced hepatocellular carcinoma; avapritinib, used in the treatment for unresectable, treatment-resistant gastrointestinal stromal tumors and advanced systemic mastocytosis; and BLU-667, for ret-mutations, fusions, and predicted resistant mutants. Its preclinical product candidate BLU-782 is intended for ALK2 mutations in fibrodysplasia ossificans progressiva. The company also discovers product candidates for kinase targets and immunokinase targets. The company operates through genomic and cancer research institutions located in the US. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

Blueprint Medicines Corp (BPMC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Blueprint Medicines Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Blueprint Medicines Raises USD50 Million in Series C Venture Financing 13

Blueprint Medicines Raises USD 25 Million In Series B Venture Financing 16

Blueprint Medicines Raises USD 40 Million In Series A Venture Financing 18

Partnerships 20

Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 20

Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 21

Licensing Agreements 22

CStone Pharma Enters into Licensing Agreement with Blueprint Medicines 22

Roche Enters into Licensing Agreement with Blueprint Medicines 24

Equity Offering 26

Blueprint Medicines Raises USD325.5 Million in Public Offering of Shares 26

Blueprint Medicines Raises USD230 Million in Public Offering of Shares 28

Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 30

Blueprint Medicines Completes IPO 32

Blueprint Medicines Corp-Key Competitors 34

Blueprint Medicines Corp-Key Employees 35

Blueprint Medicines Corp-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 01, 2018: Blueprint medicines reports second quarter 2018 financial results 37

May 02, 2018: Blueprint Medicines Reports First Quarter 2018 Financial Results 39

Feb 21, 2018: Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results 41

Oct 31, 2017: Blueprint Medicines Reports Third Quarter 2017 Financial Results 43

Aug 02, 2017: Blueprint Medicines Reports Second Quarter 2017 Financial Results 45

May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results 46

Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results 48

Research And Development 50

Jul 27, 2017: Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion 50

Corporate Communications 51

Oct 10, 2017: Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations 51

Product News 52

04/15/2018: Selective Inhibitor Shows Early Promise in Patients With RET-altered Cancers 52

03/27/2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences 53

03/27/2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences 54

Clinical Trials 55

Jun 21, 2018: Blueprint doses first patient in Voyager trial 55

Jun 15, 2018: Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity 56

May 17, 2018: Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis 59

Apr 15, 2018: Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors 60

Apr 15, 2018: Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 62

Mar 14, 2018: Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 63

Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity 64

Dec 10, 2017: Blueprint Medicines: Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder 66

Nov 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes 67

Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data 70

Nov 01, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition 71

Sep 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma 72

Aug 21, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference 74

Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 75

Aug 02, 2017: Blueprint Medicines Provides Update on Hepatocellular Carcinoma Drug BLU-554 76

Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation 77

May 17, 2017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting 79

Mar 20, 2017: Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Blueprint Medicines Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Blueprint Medicines Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Blueprint Medicines Corp, Medical Devices Deals, 2012 to YTD 2018 10

Blueprint Medicines Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Blueprint Medicines Raises USD50 Million in Series C Venture Financing 13

Blueprint Medicines Raises USD 25 Million In Series B Venture Financing 16

Blueprint Medicines Raises USD 40 Million In Series A Venture Financing 18

Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 20

Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 21

CStone Pharma Enters into Licensing Agreement with Blueprint Medicines 22

Roche Enters into Licensing Agreement with Blueprint Medicines 24

Blueprint Medicines Raises USD325.5 Million in Public Offering of Shares 26

Blueprint Medicines Raises USD230 Million in Public Offering of Shares 28

Blueprint Medicines Raises USD143.8 Million in Public Offering of Shares 30

Blueprint Medicines Completes IPO 32

Blueprint Medicines Corp, Key Competitors 34

Blueprint Medicines Corp, Key Employees 35

Blueprint Medicines Corp, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Blueprint Medicines Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person